- 2024-08-20 02:02抑制剂M1001|M1001|874590-32-6|Adamas life|≥98%（以实测数值为准）|BR|100mg
- 2024-08-20 02:02抑制剂M1001|M1001|874590-32-6|Adamas life|≥98%（以实测数值为准）|BR|25mg
- 2024-08-20 02:02抑制剂LY310762|LY310762|192927-92-7|Adamas life|≥98%（以实测数值为准）|BR|100mg
- 2024-08-20 02:02抑制剂LY310762|LY310762|192927-92-7|Adamas life|≥98%（以实测数值为准）|BR|25mg
- 2024-08-20 02:02抑制剂LysoPC(14:0/0:0)|LysoPC(14:0/0:0)|20559-16-4|Adamas life|≥98%（以实测数值为准）|BR|100mg
- 2024-08-20 02:02抑制剂LysoPC(14:0/0:0)|LysoPC(14:0/0:0)|20559-16-4|Adamas life|≥98%（以实测数值为准）|BR|25mg
- 2024-08-20 02:02抑制剂LY 344864 racemate|LY 344864 racemate|186543-64-6|Adamas life|≥98%（以实测数值为准）|BR|5mg
- 2024-08-20 02:02抑制剂LY 344864|LY 344864|186544-26-3|Adamas life|≥98%（以实测数值为准）|BR|100mg
- 2024-08-20 02:02抑制剂LY 344864|LY 344864|186544-26-3|Adamas life|≥98%（以实测数值为准）|BR|25mg
- 2024-08-20 02:02抑制剂LY 344864|LY 344864|186544-26-3|Adamas life|≥98%（以实测数值为准）|BR|5mg
- 2024-08-20 02:02抑制剂LX2343|LX2343|333745-53-2|Adamas life|≥98%（以实测数值为准）|BR|5mg
- 2024-08-20 02:02抑制剂LY 344864 racemate|LY 344864 racemate|186543-64-6|Adamas life|≥98%（以实测数值为准）|BR|100mg
- 2024-08-20 02:02抑制剂LY 344864 racemate|LY 344864 racemate|186543-64-6|Adamas life|≥98%（以实测数值为准）|BR|25mg
- 2024-08-20 02:02抑制剂LPA2 antagonist 1|LPA2 antagonist 1|1017606-66-4|Adamas life|≥98%（以实测数值为准）|BR|25mg
- 2024-08-20 02:02抑制剂LPA2 antagonist 1|LPA2 antagonist 1|1017606-66-4|Adamas life|≥98%（以实测数值为准）|BR|5mg
- 2024-08-20 02:02抑制剂LX2343|LX2343|333745-53-2|Adamas life|≥98%（以实测数值为准）|BR|100mg
- 2024-08-20 02:02抑制剂LX2343|LX2343|333745-53-2|Adamas life|≥98%（以实测数值为准）|BR|25mg
- 2024-08-20 02:02抑制剂LP-533401 hydrochloride|LP-533401 hydrochloride|1040526-12-2|Adamas life|≥98%（以实测数值为准）|BR|5mg
- 2024-08-20 02:02抑制剂LP-778902|Telotristat|1033805-28-5|Adamas life|≥98%（以实测数值为准）|BR|5mg
- 2024-08-20 02:02抑制剂LPA2 antagonist 1|LPA2 antagonist 1|1017606-66-4|Adamas life|≥98%（以实测数值为准）|BR|1mg
